journal article·2026-03Open access

Disengaging the Engine: Histone Deacetylases 1 and 2‐Mediated Acetylation of Hexokinase‐2 Regulates Energy Metabolism in Microglia Following Intracerebral Hemorrhage

Zhiwen Jiang, Heng Yang, Xinjie Gao, Zengyu Zhang, Ruiyuan Weng, Yuchao Fei, Jiabin Su, Hanqiang Jiang, Wei Ni, Yuxiang Gu

Advanced Science· Volume 13· Issue 14

Abstract

ABSTRACT Microglia‐mediated neuroinflammation is closely associated with the pathogenesis of secondary brain injury following spontaneous intracerebral hemorrhage (ICH). However, the relationship between immune response regulation and metabolic patterns in microglia remains unclear. Histone Deacetylases 1 and 2, a class of lysine deacetylases, regulates gene transcription by modulating histone acetylation modifications and is widely involved in various cellular activities of microglia. In this study, we observed that knockout of HDAC1/2 in microglia alleviated neurological deficits caused by ICH, preserved white matter integrity, and accelerated hematoma clearance post‐ICH. Mechanistically, we found that after ICH, microglia exhibited increased expression of hexokinase 2 (HK2) and enhanced glycolysis. HDAC1/2 knockout/pharmacological inhibition affected the acetylation level of HK2, inhibited its glycolytic activity, and promoted a metabolic shift in activated microglia from glycolysis to fatty acid oxidation. This shift was associated with reduced pro‐inflammatory responses and enhanced phagocytic activity in microglia. Enhanced fatty acid oxidation may have a detrimental effect on mitochondrial function, and HDAC1/2 inhibition simultaneously promoted mitophagy in microglia. Additionally, HDAC1/2 inhibition triggered microglial apoptosis and suppressed proliferation, ultimately leading to a reduction in microglial cell numbers. Overall, this study reveals the potential mechanisms by which targeting HDAC1/2, through acetylation modifications and transcriptional regulation, modulates microglial function and metabolism after ICH, thereby exerting protective effects.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Intracerebral and Subarachnoid Hemorrhage Research · Neuroinflammation and Neurodegeneration Mechanisms · Amyotrophic Lateral Sclerosis Research

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Neurosurgery Huashan Hospital of Fudan University Fudan University Shanghai China

Department of Neurology of Minhang Hospital State Key Laboratory of Brain Function and Disorders, MOE Frontiers Center for Brain Science, and Institutes of Brain Science Fudan University Shanghai China

Funding

Natural Science Foundation of Tibet Autonomous Region · Ministry of Science and Technology of the People's Republic of China · National Natural Science Foundation of China

References (57)

Show source-provided references
1. 10.1016/j.gheart.2014.01.00310.1016/j.gheart.2014.01.003 ↗
2. 10.1038/s41572‐023‐00424‐710.1038/s41572‐023‐00424‐7 ↗
3. 10.1007/s12035‐016‐9785‐610.1007/s12035‐016‐9785‐6 ↗
4. 10.1161/STROKEAHA.115.01092010.1161/STROKEAHA.115.010920 ↗
5. 10.1186/s40824‐022‐00311‐410.1186/s40824‐022‐00311‐4 ↗
6. 10.1161/CIRCRESAHA.121.31994910.1161/CIRCRESAHA.121.319949 ↗
7. 10.1073/pnas.201849711710.1073/pnas.2018497117 ↗
8. 10.1186/s12974‐019‐1640‐z10.1186/s12974‐019‐1640‐z ↗
9. 10.2147/JIR.S41623910.2147/JIR.S416239 ↗
10. 10.1177/0271678X2094261310.1177/0271678X20942613 ↗
11. 10.1016/j.immuni.2018.02.01610.1016/j.immuni.2018.02.016 ↗
12. 10.1155/2015/16314010.1155/2015/163140 ↗
13. 10.1172/JCI12904910.1172/JCI129049 ↗
14. 10.1016/j.celrep.2023.11362910.1016/j.celrep.2023.113629 ↗
15. 10.1038/s42255‐022‐00707‐510.1038/s42255‐022‐00707‐5 ↗
16. 10.1038/s42255‐022‐00643‐410.1038/s42255‐022‐00643‐4 ↗
17. 10.1111/jnc.1426710.1111/jnc.14267 ↗
18. 10.1016/j.cmet.2018.08.01210.1016/j.cmet.2018.08.012 ↗
19. 10.3389/fimmu.2020.0049310.3389/fimmu.2020.00493 ↗
20. 10.1111/bph.1313910.1111/bph.13139 ↗
21. 10.1007/s10120‐023‐01405‐110.1007/s10120‐023‐01405‐1 ↗
22. 10.1111/cas.1576310.1111/cas.15763 ↗
23. 10.1038/s41467‐021‐22163‐710.1038/s41467‐021‐22163‐7 ↗
24. 10.1111/cns.1464610.1111/cns.14646 ↗
25. 10.1126/sciadv.ade690010.1126/sciadv.ade6900 ↗
26. 10.1111/febs.1532710.1111/febs.15327 ↗
27. 10.1002/iub.253110.1002/iub.2531 ↗
28. 10.1038/s41580‐020‐00324‐810.1038/s41580‐020‐00324‐8 ↗
29. 10.1038/nprot.2016.16910.1038/nprot.2016.169 ↗
30. 10.1007/s12539‐019‐00327‐w10.1007/s12539‐019‐00327‐w ↗
31. 10.1080/15548627.2022.210230910.1080/15548627.2022.2102309 ↗
32. 10.1016/j.neuropharm.2022.10896310.1016/j.neuropharm.2022.108963 ↗
33. 10.3390/cancers1103031710.3390/cancers11030317 ↗
34. 10.1038/nrneurol.2017.6910.1038/nrneurol.2017.69 ↗
35. 10.1186/s12974‐021‐02318‐510.1186/s12974‐021‐02318‐5 ↗
36. 10.1002/glia.2448210.1002/glia.24482 ↗
37. 10.1126/scitranslmed.abe564010.1126/scitranslmed.abe5640 ↗
38. 10.1038/s41593‐019‐0566‐110.1038/s41593‐019‐0566‐1 ↗
39. 10.3390/antiox1101002210.3390/antiox11010022 ↗
40. 10.1016/j.cmet.2024.03.01410.1016/j.cmet.2024.03.014 ↗
41. 10.1016/j.jbc.2024.10570410.1016/j.jbc.2024.105704 ↗
42. 10.1186/s13046‐020‐1528‐x10.1186/s13046‐020‐1528‐x ↗
43. 10.1038/nature1649810.1038/nature16498 ↗
44. 10.1016/j.etap.2015.12.00410.1016/j.etap.2015.12.004 ↗
45. 10.1126/scitranslmed.abg307210.1126/scitranslmed.abg3072 ↗
46. 10.3390/ijms2101023410.3390/ijms21010234 ↗
47. 10.1186/s12974‐021‐02187‐y10.1186/s12974‐021‐02187‐y ↗
48. 10.1186/s12951‐024‐02560‐y10.1186/s12951‐024‐02560‐y ↗
49. 10.1016/j.arr.2023.10203210.1016/j.arr.2023.102032 ↗
50. 10.1038/s41589‐019‐0462‐810.1038/s41589‐019‐0462‐8 ↗
51. 10.1016/j.ejphar.2022.17522610.1016/j.ejphar.2022.175226 ↗
52. 10.3390/cancers1201010910.3390/cancers12010109 ↗
53. 10.3390/ijms1912395210.3390/ijms19123952 ↗
54. 10.3390/cells1005100110.3390/cells10051001 ↗
55. 10.1111/febs.1512210.1111/febs.15122 ↗
56. 10.1258/la.2010.001002110.1258/la.2010.0010021 ↗
57. 10.14336/AD.2017.032810.14336/AD.2017.0328 ↗